A Novel Device to Improve the Tolerability of Intranasal Corticosteroid Sprays for Allergic Rhinitis and Postoperative Chronic Rhinosinusitis: A Crossover Trial.
Sethmi Ranasinghe, Xenia Berger, Wandia Kimita et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated a novel nasal adaptor for metered-dose inhalers (MDIs) in patients with allergic rhinitis (AR) and postoperative chronic rhinosinusitis (CRS). Sixteen participants in each group used both a standard fluticasone nasal spray and the MDI with adaptor. Results showed that 69% preferred the MDI, reporting fewer unpleasant sensations, which may enhance compliance and symptom control.
Key findings
- 69% of participants preferred the MDI with adaptor over the standard nasal spray.
- Satisfaction scores improved significantly with the novel device in the CRS cohort.
- Participants indicated a higher likelihood of compliance with the MDI with adaptor.
Why it matters
Improving the tolerability of intranasal corticosteroids can enhance patient compliance, which is crucial for effective management of allergic rhinitis and chronic rhinosinusitis. This study suggests that a novel device may facilitate better adherence to treatment.